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Bone marrrow-derived T progenitor cells undergo proliferation and maturation
under the influence of the thymic microenvironment (1). Only a small fraction of
thymocytes are selected to account for selftolerance, as well as self restriction, and
become immunocompetent T cells (2). The molecularand cellular mechanisms for
the growth and maturation of thymocytes are poorly understood.
Cell surface phenotype analyseshaveshownthat thymocytes are composed ofhighly
heterogeneous populations. Based on cell surface expression ofthe TCR accessory
molecules CD4 and CD8, thymocytes can be divided into three major subpopula-
tions, which generally are thought to relate to maturation stages. They are the
CD2+CD1-CD4-8- (double-negative) cells, CD2'CD1'CD4'8' (double-positive)
cells, and CD2'CDl-CD4'8- or CD2'CDl-CD4- 8' (single-positive) mature
thymocytes. Both double-negative and double-positive thymocytes areimmature cells
located in the cortical compartment of human thymus (3). Mature thymocytes do
not expressthe cortical specific marker CD1 but expressTCRA and B chain subunits
associated with the CD3 complex and reside predominantly in the medullary com-
partment (4). The three major populations can be further subdivided using other
cell surface antigens as markers.
All populations of thymocytes can express IL-2-Rs (5), and double-negative as
well as single-positive thymocytesare able to secrete IL-2. IL-2 induction in thymo-
cytes requires stimulation bycombinations ofTcell mitogens: PHAor ConA, PMA,
ionomycin, and anti-CD2 antibodies (6). Previous studies have shown that certain
combinations of anti-CD2 mAbs can trigger peripheral T cell proliferation in the
absence ofmacrophages (7, 8). In contrast to peripheral T cells, thymocytes are un-
able to proliferate in response to CD2 stimulation, although IL-2-R expression will
be induced on CD2-stimulated thymocytes (5). Single-positive thymocytes, although
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phenotypically indistinguishable from peripheral T cells, apparently require fur-
ther differentiation to become immunocompetent. The mechanisms via which the
relatively small pool of selected, mature thymocytes expand and differentiate into
mature, peripheral T lymphocytes is presently unknown.
Previous studies have shown that anti-CD2 antibodies, 9-1 and 9.6, trigger pe-
ripheral T cell proliferation that can be augmented by addition of anti-CD3 anti-
bodies (8). The T cell lineage-specific CD28 molecules are also involved in T cell
activation in combination with PMA (9, 10) . Based on previous work that anti-CD3
and anti-CD28 independently potentiates CD2-mediated T cell activation (11), we
found it of interest to study the effects of these T cell mitogenic antibody combina-
tions on thymocytes.
The present study demonstrated that mitogenic combinations of anti-CD2 anti-
bodies together with an anti-CD28 antibody triggers vigorous mature thymocyte
proliferation. This cell proliferation was mediated via IL-2 production by autocrine
stimulation of IL-2-R . It was observed that only the thymocytes with mature pheno-
type were able to secrete IL-2 in response to these stimuli. The CD28 molecule (Tp44,
9.3 or Kolt-2) has previously been implicated in an antigen-independent pathway
for mature T cell activation (12, 13). These findings together with our data would
suggest that the CD2 and CD28 molecules are involved in controlling the expansion
and maturation of terminally differentiated thymocytes, and may also regulate self-
renewal of the peripheral mature T cell pool .
Materials and Methods
Cell Preparation.
￿
Thymic tissue was obtained from children (1 d to 8 yr old) undergoing
cardiovascular surgery. Thymocytes were separated, purified, and frozen as previously de-
scribed (14), or used fresh in the experiments. Thymocyte subpopulations were prepared by
the panning method or by cell sorting. Thymocytes, suspended in RPMI 1640 with 0.25%
human serum albumin (Armour Pharmaceutical Co., Kankakee, IL) and 25 mM Hepes (Sigma
Chemical Co., St. Louis, MO), were reacted with a mixture ofanti-CD4 (Leu-3a) and anti-
CD8 (Leu-2a) or with anti-CDl (NAl/34) for isolation of double-negative cells and CDl -
or CDl' thymocytes, respectively. After incubating 30 min at 4°C, the cells were washed
and either labeled with goat anti-mouse Ig FITC-F(ab)z or used for panning. The labeled
cells were sorted using a FAGS (Coulter EPICS 753 ; Coulter Electronics Inc., Hialeah, FL).
The purity of negatively selected thymocyte subpopulations was assessed by indirect im-
munofluorescence assays using appropriate mAbs and was always <3 % contaminating cells.
The CD1' thymocytes were >90% CDl'.
mAbs.
￿
Anti-CD2 mAbs 9-1 (IgG3), 9 .6 (IgG2a), and anti-CD28 mAb 9.3 (IgG2a) were
used at a final concentration of 5 jig/ml unless otherwise indicated. mAb 9.3 and 9.6 were
gifts from Dr. John A. Hansen, Fred Hutchinson Cancer Research Center, Seattle, WA; the
mitogenic anti-CD3 mAb SP34 (IgG2a) was a gift from Dr. Cox Terhorst, Dana Farber Cancer
Institute, Boston, MA. The anti-CD25, Tac was purchased from Becton Dickenson & Co.
(Mountain View, CA), and the anti-CD25 (T25E) was locally produced at Sloan-Kettering
Institute (New York, NY).
Proliferation Assay.
￿
Thymocyte proliferation assays were performed as previously described
(8, 14). Briefly, thymocytes (105) were cultured in a 96-well plate in 0.2 ml of RPMI 1640
supplemented with 15% human A serum (Plasma Alliance, Inc., Knoxville, TN) for 5 d.
[3H]Thymidine (0.5 lGi/well) was added during the final overnight culture. Anti-CD2 an-
tibodies at 5 ug/ml, anti-CD28 (9.3 or KOLT2) at 5 4g/ml or 1:5,000 dilution of ascites un-
less otherwise indicated, and anti-CD3 (SP34) at 1 :10,000 dilution of ascites were used in
the cultures for thymocyte stimulation. Purified human monocyte IL-1 from Dr. Charles
Dinarello (Tufts University School ofMedicine, Boston, MA) was added at a final concentra-YANG ET AL.
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tion of 5 U/ml and rIL-2 (Cetus Corp., Emeryville, CA) was used at 10 U/ml. Results repre-
sent the mean cpm of triplicate samples, with SEM <10% in the majority of the cases.
Northern Blot Analysis. Dot blot analysis was performed with cytoplasmic mRNAobtained
from lysing thymocytes that had been cultured for 30 hat 2 x 106/ml in the presence of
mAbs. Pilot time-course experiments showed that IL-2 transcripts reached a peak at -30
h ofstimulation, whereas IL-2 in the supernatants peaked at 48 h of culture. The thymocytes
were lysed in a 4 M guanidine thiocyanate solution and chromosomal DNA was sheared.
The mixture was layered on a 5.7 M CsCl cushion and spun at 34,000 rpm for 18 h at 4°C.
The RNA was resuspended in distilled waterand then ethanol-precipitated and resuspended
again in distilled water(15). The extracted RNA was dotted onto the nylon membrane (New
England Nuclear, Boston, MA). Each dot contained a total RNA from 50 x 106 thymocytes
counted at the start of culture. The hybridization was performed at 42 °C in the presence
of formamide with a 32P-labeled IL-2 probe (16), an IL-2-R probe (17), or class I HLA probe
(pHLA-B7), and the membrane was washed with 0.015 M NaCI/0.015 M Na Citrate/0.5%
NaDoS04 at 65 °C. The membranes were dehybridized by boiling the membrane for 3 min
in 0.0015 M NaCI/0.0015 M Na Citrate/0.01% NaDoS04 . The results were analyzed on the
autoradiogram.
Quantitation of IL-2.
￿
Supernatants were collected from thymocyte cultures prepared for
Northern blot analysis at 30 and 48 h after stimulation. The cell-free supernatants were tested
for IL-2 content by the standard bioassay method using the IL-2-dependent murine cell line
CTLL. The CTLL line in log phase (4,000 cells/well) was plated in a 96-well flat-bottomed
microtiter plate (200 ul). Test samples were added in triplicate to the microtiter plate. After
24 h of culture, the cells were pulsed with 0.5 lCi [3H]thymidine for the last 4 h of culture
and harvested onto filter strips. Results were expressed with 1 U of IL-2 calculated from IL-2
standards.
Immunofluorescence (IF)' Staining and Flow Cytometry.
￿
Cells were reacted with mAbs for 15
min and washed twice with IF buffer (PBS containing 1% BSA and 0.02% sodium azide).
The washed cells were then incubated with goat anti-mouse IgG, F(ab)2 FITC (Cappel
Laboratories, Cochranville, PA) for an additional 15 min and washed with IF buffer. All IF
staining procedureswere performed on ice. For direct immunofluorescence, cells were directly
stained with FITC- or phycoerythrine-conjugated mAbs. The stained cells were resuspended
in PBS and were analyzed by FACS.
Results
Activation of Thymocytes Via CD2 and CD28 Triggering .
￿
We have investigated the
ability of mAbs to CD28, CD2, and CD3 to induce thymocyte proliferation. Fig.
1 shows that unfractionated thymocytes were unresponsive to mitogenic combina-
tions of anti-CD2 (9-1 plus 9.6) antibodies. A vigorous thymocyte proliferation was,
however, obtained in a dose-dependent manner with anti-CD28 (9.3), but not with
anti-CM (SP34) when costimulated with the anti-CD2 combination. Optimal thymo-
cyte proliferation was obtained at 1 wg/ml of 9.3 antibody with 5 gg/ml of 9-1 and
9.6 antibodies. No differences in responses were observed within a range between
1 and 10 gg/ml of 9.3. These findings are in contrast to the results obtained from
peripheral mature T cells that proliferate in vitro in response to anti-CD2 (9-1 plus
9.6) alone as well as to the combination of anti-CD2 plus and anti-CM (8).
To determine the proliferative potential ofthe thymocytestriggered by thesemito-
genic antibody combinations, macrophage-derived IL-1 and HL-2 were added to
unfractionated thymocyte cultures (Table I). Neither exogenous IL-1 nor exogenous
IL-2 affected thymocytes cultured with 9-1, 9 .6, or 9.3 alone, nor with 9-1 plus 9.3.
The anti-CD2 combination 9-1 plus 9.6 could induce IL-2 responsiveness, but not
I Abbreviation used in this paper: IF, immunofluorescence.1460
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FIGURE 1.
￿
Dose response ofanti-CD28 (9-3) and anti-CD3 (SP34)
for thymocyteproliferation in thepresence of optimal concentra-
tion of anti-CD2 (9-1 plus 9.6)antibodies. Unfractionated thymo-
cyteswere stimulated with differentconcentrations of9.3 andSP34
as indicated in the presence of a mixture of 5 ug/mleach of 9-1
and9.6. Thymidineuptake wasmeasured after96 hofcell culture
as described in Materials and Methods.
IL-1 responsiveness. Interestingly, addition ofIL-1 to the anti-CD28 (9.3) plusanti-
CD2 (9-1 plus9.6) combination augmented thymocyte proliferation as much as the
addition of exogenous IL-2 to the culture (Table I).
CD28/CD2 Triggering ofThymocytes Induces IL-2 and IL-2-R Expression.
￿
Previous
studieshave shownthatcertain subsets ofthymocytes ormature Tcells can proliferate
in vitro without IL-2-R or IL-2 (18). To determine whether the IL-2-IL-2-R inter-
action regulates thymocyte proliferation triggered by themitogenic9-1/9.6/9.3 com-
bination, we have performed IL-2 inhibition assays. Two mAbs (Tac and T25E)
directed against IL-2-R completely blocked thymocyte proliferation inducedbythe
mitogenic antibody combination (Fig. 2). This result indicated that the thymocyte
proliferation induced by anti-CD2 plus anti-CD28 was IL-2 dependent. This result
was further substantiated by Northern blot analysis for IL-2 and IL-2-R gene ex-
pression in thymocytes. Thymocytes were cultured for 30 h in the presence ofvar-
ious combinations of mAbs as indicated in Fig. 3, and the isolated MRNA was as-
sayed for IL-2 and IL-2-R transcripts.
TABLE I
Proliferation Response of the Unfractionated Thymocytes to the
Anti-CD2 andAnti-CD28 in the Presence and Absence of
Exogenous IL-1 and IL-2
One of at least five experiments.
9-1
Stimulators
9.6 9.3 Medium
cpm x
IL-1
10-31105 cells
IL-2
- - - 0.1 0.3 1.0
- - + 0.2 0.2 1.4
+ - - 0.3 0.3 1.6
+ - + 0.6 0.2 2.8
- + - 0.1 0.2 1 .4
- + + 0.1 0.3 2.2
+ + - 0.1 0.3 37 .1
+ + + 93.1 212.6 212.2a
0
X
a V
YANG ET AL .
￿
146 1
FIGURE 2 .
￿
IL-2 inhibition assay for thymocyte proliferation induced
by theCD2 and CD28-mediated activation using anti-IL-2-R anti-
bodies . Thymocytes were stimulated with a mitogenic combination
ofmAbs (9-1/9.6/9.3) in the presence ofvarious dilution of anti-IL-2-
R, Tac, andT25E .Mouse ascitic fluidP3 with no specificity was used
as a negative control .
IL-2-R transcripts were detected in thymocytes cultured with an anti-CD2 com-
bination (9-1 plus 9.6) . Addition of anti-CD28 (9.3) induced IL-2 as well as aug-
menting expression of IL-2-R messages suggesting that the secreted IL-2 may up-
regulate its own receptor on thymocytes . Alternatively, the synergistic stimulation
viaCD2 andCD28mayhave augmenting effects on IL-2-R induction . As expected
FIGURE 3 .
￿
Northern dot blot analysis for induction of the
IL-2 andIL-2-R transcript and bioassay for IL-2 measure-
ment . Thymocytes were cultured in the presence ofvarious
combinations ofmAbs as indicated . After30hof cell cul-
tures, RNA was isolated, blotted (50 x 106 cells/dot), and
hybridized with DNAprobes as described in Materialsand
Methods . A portion ofthe cellswas cultured further to 48
h, andthe supernatantswere collected. IL-2 released in the
supernatants was bioassayed using IL-2-dependent mouse
cell line CTLL .1462
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from the results obtained from proliferative assays, anti-CD28 alone or anti-CD3
(SP34) alone had no effect on the expression of IL-2-R transcripts as shown in Fig.
3. As predicted from the above functional studies, 9-1 plus 9.6 did not induce the
expression of IL-2 transcripts. In contrast to the results obtained from peripheral
mature T cells, addition of anti-CD3 to the anti-CD2 stimulation did not have any
effect on IL-2 induction. C132-mediated IL-2-R induction without IL-2 secretion
by thymocytes is consistent with previous observations (5). Stimulation by anti-CD2
(9-1 plus 9.6) and anti-CD28 (9 .3) induced IL-2 transcripts in thymocytes, which
is consistent with the proliferative in vitro results shown above. Aconsiderable amount
of secreted IL-2 was detected in the culture supernatants when thymocytes were
activated by the anti-CD2 and anti-CD28 as shown in Fig. 3. None of the other
antibody combinations had any effect on IL-2 transcript induction.
CD2/CD28 Triggering is Selectivefor the CDI", Mature Thymocyte Pool.
￿
Recent studies
have shown that the immature CD4- 8- thymocytes have the capacity to secrete
IL-2 and to express IL-2-R resulting in proliferation (6). We have examined the
double-negative thymocytes for their proliferative responses mediated via the CD2
and CD28 activation pathway. The CD4- 8- thymocytes were negatively selected
by a cell sorter after staining the freshly thawed thymocytes with a mixture of Leu-
2a (anti-CD8) and Leu-3a (anti-CD4) antibodies. None of the antibody combina-
tions were able to trigger the CD4- 8- cells, while unfractionated thymocytes
responded as expected (Table II). Double-negativethymocytes obtained by panning
procedure gave similar results (data not shown). However, the mitogenic combina-
tion 9-1/9.6/9.3 induced a vigorous proliferation of the cells positively selected for
CD4+ and CD8+ expression (data not shown). However, the data were difficult to
interpret since the positively selected cells also contained both double-positive and
single-positive cells. Furthermore, antibodies bound to thymocytes could potentially
exert either a positive or negative effect on cell membranes.
To overcome thesedifficulties, the double-positive thymocyte population was iso-
lated by cell sortingusing theCD1 cell surface marker. CDI molecules are predomi-
nantly expressed on immature thymocytes, particular by intermediate CD4+8+
TABLE II
Activation of Highly Purled Double-negative (CD4 - 8- )
Thymocytes by Anti-CD2 and Anti-CD28
' The double-negative thymocytes were negatively selected by FAGS after staining
with a mixture of anti-CD4 (Leu-3a) and anti-CD8 (Leu-2a) mAbs.
1 cpm obtained by stimulation of 9-1 + 9.6 + 9 .3.
Stimulators - Exp. 1 Exp. 2
cpm x 10-31105 cells'
Medium control 0.2 0.6
9-1 + 9.3 0.2 0.4
9 .6 + 9.3 0.3 0.2
9-1 + 9.6 0.1 0.5
9-1 + 9.6 + 9 .3 0.2 1 .0
Total thymocytes 51.81 75 .71YANG ET AL .
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TABLE III
Proliferation Responsesfor the CD1+ and CDI - Thymocytes
Triggered by Anti-CD2 andAnti-CD28
' The CDl+ and CDI- thymocytes were sorted by FACS after staining with
anti-CDI mAb NA1/34 .
cells, and CD1 expression is lost on the mature single-positive cells (4). Table III
shows the proliferative response of the CD1+ and CDI - subsets when stimulated
with the anti-CD2 and anti-CD28 antibodies . The subpopulations were sorted after
fluorescence staining with the anti-CD1 (NA1/34) antibody. The 9-1/9.6/9.3 stimu-
lation consistantly triggered proliferation of the CD1- cells, but a greatly reduced
proliferative response was obtained for the CD1+ cells (Table III) . These results,
obtained from the CD4"8- fraction together with data from the CDl+ andCD1-
cells, indicated that only the mature single-positive thymocytes have the capacity
to proliferate via the CD2 and CD28 activation pathway .
Thein vitro proliferative studiesdemonstrated that theanti-CD2 plusanti-CD28
responsive thymocytes arethe mature thymocytes . These resultswere consistent with
data obtained by staining thymus sections with mAb 9.3 (Fig. 4) and cytofluoro-
graphic analysis of thymocytes (Fig . 5) . The anti-CD28 stained brightly the medul-
lary section, which contains mature thymocytes (Fig. 4 B), with rare cells in the
thymus cortex reacting with theCD28 antibody (Fig. 4A) . FACS analysis of unfrac-
tionated cryopreserved thymocytes showed that 55% of thymocytes were positive
for anti-CD28 (9 .3) with a relatively low intensity, whereas 70% were stained with
anti-CD3 (Leu-4). This high percentage ofCD28+ thymocytes (Fig. 5 a) indicated
that the CD28+ subset survived preferentially from the cryopreservation and
thawing process, sincethe percentage profilefor CD28 antigens on fresh thymocytes
was 10-20% in several experiments . Two-color analysis of thymocytes showed that
the majority ofCD28+ cells were also CD3+ cells : 39% were CD28+/CD3+, 24 ,70
CD28 -/CD3+, 6% CD28+/CD3`, and 31o7o CD28-/CD3 - (data not shown) . It re-
mains to be determined if there are differences in the capacity of theCD28+/CD3-
and CD28+/CD3+ thymocytes to respond to costimulation with anti-CD2 and
anti-CD28.
Culture conditions Exp. 1 Exp . 2
cpm x 10-31105 cells
Total thymocytes
Medium control 0.1 0.1
9-1 + 9.6 0.1 0.3
9-1 + 9.6 + 9.3 36.0 116.5
CD1+ thymocytes'
Medium control <0.1 0.1
9-1 + 9.6 <0 .1 0.1
9-1 + 9.6 + 9.3 0.3 15.4
CD1- thymocytes'
Medium control <0 .1 0.1
9-1 + 9.6 <0.1 0.2
9-1 + 9.6 + 9 .3 52 .1 78 .81464
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Discussion
Our results demonstrated that CD1 - mature thymocytes can proliferate in vitro
in an autocrine fashion when triggered by acombination ofCD2 andCD28 mAbs
in the absence of exogenous cytokines . We used two anti-CD2 antibodies (9-1 plus
FIGURE 4 .
￿
Human thymus cross section stained with anti-CD28 (9.3). (A) The reactivity of
mAb 9.3 with thymocytes in the thymic cortical zone. Solid arrows point to 9.3' thymocytes,
and open arrows denote autofluorescent (9 .3 - )pigment . (B) The reactivity of 9.3 with thymo-
cytes in the thymic medullar. H identifies a Hassall'sbody region . Most medullary thymocytes
are 9.3*, whereas few cortical thymocytes are 9.3' (x 400) .
b
FIGURE 5 .
￿
Reactivity patterns for CD28 andCD3 on
unfractionated thymocytes by FAGS. Thymocytes were
Log Fluorescence Intensity
￿
indirectly stained with 9.3 (anti-CD28) (a) and Leu-4
(anti-CD3) (6) . In this experiment, 55% ofthymocytes
reacted with mAb 9.3, while 70% reacted with mAb
Leu-4.YANG ET AL.
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9.6), which can trigger peripheral mature T cell proliferation in theabsenceofmac-
rophages (8), together with an anti-CD28 antibody, which is also mitogenic for T
cells in combination with PMA (9, 10). The anti-CD2 combination alone or anti-
CD28 alone rendered no effect on thymocyte proliferation. Addition of anti-CD3
to the anti-CD2 combination, whichnormally augments proliferationof mature pe-
ripheral T cells (8), did not drive thymocytes to proliferate. We have found that the
proliferative thymocyte response to the anti-CD2 plus anti-CD28 antibody combi-
nation was confined to the thymocyte subset of mature cells with the phenotype of
CD3+CD1-/CD4' or CD8+. These results indicate that, in contrast to peripheral
T cells, thymocytes are unable to respond in the absence of exogenous cytokines
to triggering signals via CD2 or CD3/Ti pathways in spite of their mature pheno-
type. However, as previously reported (5), thymocytes treated with the anti-CD2
combination were able to proliferate in the presence of exogenous IL-2, indicating
that the activation block in thymocytes is in the production of endogenous IL-2 .
Previous studieshave also shown that stimulation oftheCD3/Ti complex on thymo-
cytes by anti-CD3 inhibit IL-2 gene activation, which can be induced by the mito-
genic anti-CD2 antibody combination plus PMA (19). Taken together these results
would imply that CD3' mature thymocytes are functionally distinct from periph-
eral mature T lymphocytes despite their mature phenotype. The CD3/Ti interac-
tions with selfMHC products in thethymus couldthereby function as adown-regu-
lation signal for the selection against autoreactive T cell precursors as has recently
been suggested (19).
Our study demonstrates that the majority of the CD28+ thymocytes are CD3+.
These CD28+/CD3 + cells are localized primarily within the medullary compart-
ment of the thymus (Fig. 4), where mature thymocytes reside. Growing evidence
indicates that proliferation is associated with maturation of thymocytes, and IL-2
is the likely rate-limiting factor for thegrowth of some thymocyte subsets(20). Since
virtually all cells in the T cell lineage including all stages of thymocytes express the
CD2 antigen, it is tempting to speculate that activation of the CD2 antigen plays
an important role in intrathymic mediationof thymocyteproliferation. Ourpresent
studyprovides evidence that thecombination ofactivation signals to CD2 and CD28
could account for such cell proliferation signals for the mature stage III thymocytes.
The CD28 antigen is a T cell lineage-specific cell surface molecule first defined
by mAb 9.3 (21). Previous studies have shownthat activation ofthe CD28 molecule
has a synergistic effect on PMA-induced activation of protein kinase C, resulting
in IL-2 production and IL-2-R expression causingvigorous T cell proliferation (9,
10). The CD28-mediated T cell activation is dependent upon accessory cells (12,
13) as is also the case for T cells activated via CD3/Ti (22). Ourstudydemonstrates
that macrophage-derived IL-1 augments thymocyte proliferation triggered by costimu-
lation with anti-CD28 and anti-CD2 (9-1 plus 9.6). IL-1 did not have any effect on
thymocytes stimulated with the mitogenic anti-CD2 antibody combination alone.
These results would indicate that IL-1 plays a role in CD28-triggered thymocyte
proliferation. This is consistent with data demonstratingthat IL-1 acts as a cofactor
for thymocyte activation (23).
A functional interaction betweenthe CD3/Ti complexand CD2 suggests that phys-
iologicactivation ofCD3/Ti involves acascade ofevents in whichtheCD2 molecule
plays acentral role (8, 24). Anti-CD28 triggers mature thymocyteproliferationwhen1466
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added to mitogenic anti-CD2 antibodies as shown in the present study. Anti-CD28
also potentiate peripheral T cell proliferation induced by anti-CD2 stimulation (11).
These findings suggest that there are two distinct pathways for T cell activation: an
antigen-specific activation pathway involving CD3/Ti and CD2, and an antigen-
independent pathway involving CD28 and CD2. Activation of the CD3/Ti complex
on mature thymocyteresults in down-regulation of IL-2 gene expression (19), providing
aselective advantage for CD28/CD2 activation of these cells. This observation sug-
gests that both of these activation pathways are involved in selection and expansion
ofthymocytes as well as regulation ofthe peripheral T cell pool. Cellular regulation
of these two T cell activation pathways is probably achieved by second intracellular
messengers such as CAMP and cGMP. It has been previously shown that CD28-
mediated activation elevates intracellular cGMP levels (25, 26), whereas the CD3/Ti-
mediated T cell activation increases cAMP levels (27) .
Recent studieshave demonstrated that the CD28 molecule has physical and func-
tional characteristics that are very similarto the antigen-specific TCR molecule (10,
12); both belong to the Ig super gene family (28, 29). These findings could reflect
an evolutionary relationship between the antigen-specific TCR (Ti) and the CD28
molecule. Both of these molecules could have maintained a common functional in-
teraction with the CD2 molecule resulting in identical functional end effects, i.e.,
T cell activation and cell proliferation mediated via IL-2 production and IL-2-R
gene expression. The Ti molecule evolvedinto adiverseset of antigen-specific receptor
molecules, while theCD28 molecule became the receptor for apresently unidentified
ligand responsible for recruitment of mature T cells.
The CD28 molecule is expressed on -95% of peripheral CD4+ T cells and on
N50% of peripheral CD8+ T cells (30). These CD28+ mature, peripheral T cells
could provide a peripheral T cell compartment from which fully differentiated ma-
ture T cells can be recruited when required. The CD28 - peripheral T cells would
in this model contain the fully differentiated antigen-specific T cell compartment,
which can only be activated and expanded via CD3/Ti antigen-specific activation.
The present study demonstrates a novel activation pathway for mature thymo-
cytes involving CD28 and CD2. This activation pathway is also functional in pe-
ripheral mature T cells expressing CD28 . The data presented support a model for
maturation and expansion of mature thymocytes in their transition from thymo-
cytes to the periphery. The CD28/CD2 pathway is antigen independent and may
therefore function by regulating and maintaining the peripheral T cell pool. It is
speculated that the CD28/CD2 antigen-independent T cell activation pathway, and
the CD3/Ti/CD2 antigen-specific pathway are the twomajor systems forregulation
and expansion of mature T lymphocytes.
Summary
Priorstudies have shownthat thymocytes, unlike peripheral Tcells, do notproliferate
in response to mitogenic combinations ofanti-CD2 mAbs. The present studydemon-
strated that stimulation by a mitogenic anti-CD2 combination (9-1 plus 9.6) with
anti-CD28 induced vigorous thymocyte proliferation in the absence of exogenous
IL-2. This thymocyte proliferation was IL-2 dependent as shown by the complete
inhibition using anti-IL-2-R mAbs. Induction of IL-2-R transcripts was detected
in thymocytes stimulated by the anti-CD2 antibody combination alone or the anti-YANG ET AL.
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CD2 combination plus anti-CD28 antibody. However, induction ofIL-2 transcripts
was observed only in thymocytes triggered jointly by the anti-CD2 combination plus
anti-CD28 antibodies. The double-negative (CD4- 8- ) or CD1' thymocytes isolated
by sorting or by panning were unresponsive to CD2/CD28 triggering. The same
mitogenic signal could induce vigorous proliferation of thymocytes with a mature
phenotype, i.e., CD3+ CD4+ or CD3 + CD8' thymocytes. Immunofluorescence
studies demonstrated that the majority of CD3 + thymocytes were CD28+ , and most
of the CD28+ cells were located in the medullary compartment of thymus. These
results indicated that the T cell lineage surface molecules CD28 and CD2 are in-
volved in the regulation ofexpansion and further differentiation ofmature thymocytes.
The authors wish to thank Drs.J. A. Hansen, P. J. Martin, andJ. A. Ledbetter for providing
the 9.3 mAb.
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